J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0091270007301800v1
47/7/834    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lasseter, K. C.
Right arrow Articles by Murphy, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lasseter, K. C.
Right arrow Articles by Murphy, M. G.

PHARMACOKINETICS

Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects

Kenneth C. Lasseter, MD, Jay Gambale, PharmD, Bo Jin, PhD, Art Bergman, PhD, Marvin Constanzer, MS, James Dru, MS, Tae H. Han, PhD, Anup Majumdar, PhD, Judith K. Evans, MD and M. Gail Murphy, MD

From the Clinical Pharmacology Research Unit, Clinical Pharmacology of Miami, Inc, Hialeah, Florida (Dr Lasseter) and Merck Research Laboratories, West Point, Pennsylvania (Dr Gambale, Dr Jin, Dr Bergman, Mr Constanzer, Mr Dru, Dr Han, Dr Majumdar, Dr Evans, Dr Murphy).

Fosaprepitant is an intravenous formulation of aprepitant, an oral NK1 antagonist used to prevent chemotherapy-induced nausea and vomiting. This randomized study was designed to evaluate fosaprepitant in polysorbate 80 vehicle for tolerability and bioequivalency to aprepitant. Tolerability was assessed by physical and laboratory examinations and adverse events. Plasma collected for 72 hours was assayed for aprepitant and fosaprepitant. Analysis of variance models were applied to natural log-transformed aprepitant area under the curve (AUC) data. Fosaprepitant up to 150 mg (1 mg/mL) was generally well tolerated. Fosaprepitant 115 mg was AUC bioequivalent to aprepitant 125 mg; the 90% confidence interval for the geometric mean ratio of aprepitant AUC for fosaprepitant 115 mg/aprepitant 125 mg fell within prespecified equivalence bounds of 0.80 to 1.25.

Key Words: Fosaprepitant • aprepitant • bioequivalency • tolerability

Address for correspondence: Kenneth C. Lasseter, MD, Vice President and Medical Director, Clinical Pharmacology Research Unit, Clinical Pharmacology of Miami, Inc, 550 West 84th Street, Hialeah, FL 33014; e-mail: kclasseter{at}gmail.com.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Clinical Pharmacology